A celebratory tone permeated Shire PLC's earnings call Feb. 16, as typically all-business CEO Flemming Ornskov made multiple references to the recent success of Bayern Munich on the soccer pitch while overviewing a year in which the specialty pharma reported 79% year-over-year sales growth.
Shire conceded that adding Baxalta Inc.'s portfolio to its own spurred much of the revenue uptick reported for full-year...








